{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT05020678",
            "orgStudyIdInfo": {
                "id": "NKX019-101"
            },
            "organization": {
                "fullName": "Nkarta, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers",
            "officialTitle": "A Phase 1 Study of NKX019, a CD19 Chimeric Antigen Receptor Natural Killer (CAR NK) Cell Therapy, in Subjects With B-cell Malignancies",
            "therapeuticArea": [
                "Oncology and Hematology",
                "Other"
            ],
            "study": "intravenous-allogeneic-chimeric-antigen-receptor-natural-killer-cells-car-nk-in-adults-with-b-cell-cancers"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2021-08-20",
                "type": "ACTUAL"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-08",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2038-12",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2021-08-20",
            "studyFirstSubmitQcDate": "2021-08-20",
            "studyFirstPostDateStruct": {
                "date": "2021-08-25",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-19",
            "lastUpdatePostDateStruct": {
                "date": "2024-03-21",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Nkarta, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": false,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "This is a single arm, open-label, multi-center, Phase 1 study to determine the safety and tolerability of an experimental therapy called NKX019 (allogeneic CAR NK cells targeting CD19) in patients with relapsed/refractory non-Hodgkin lymphoma (NHL), chronic lymphocytic leukemia (CLL) or B cell acute lymphoblastic leukemia (B-ALL)",
            "detailedDescription": "This is a dose-finding study of NKX019 and will be conducted in 2 parts:\n\nPart 1: dose finding utilizing a \"3+3\" enrollment schema and safety lead-in to confirm dose for NKX019 in combination with rituximab expansion cohorts (as applicable) Part 2: dose expansion to further evaluate safety and tolerability, cellular kinetics, pharmacodynamics and anti-tumor response in expansion cohorts of patients with large B cell lymphoma (LBCL), mantle cell lymphoma (MCL), indolent lymphoma (IL), Waldenstr\u00f6m macroglobulinemia (WM), CLL/ small lymphocytic lymphoma (SLL), and B-ALL."
        },
        "conditionsModule": {
            "conditions": [
                "Lymphoma, Non-Hodgkin",
                "B-cell Acute Lymphoblastic Leukemia",
                "Large B-cell Lymphoma",
                "Mantle Cell Lymphoma",
                "Indolent Lymphoma",
                "Waldenstrom Macroglobulinemia",
                "Chronic Lymphocytic Leukemia",
                "Small Lymphocytic Lymphoma",
                "Aggressive Lymphoma",
                "Large-cell Lymphoma"
            ],
            "keywords": [
                "CD19",
                "CAR",
                "Allogeneic",
                "Natural killer",
                "ACR",
                "NKX019",
                "IL15",
                "Interleukin 15",
                "NK cell",
                "Cell Therapy",
                "Immunotherapy",
                "Adoptive cell therapy",
                "r/r NHL",
                "r/r B-ALL",
                "r/r MCL",
                "r/r IL",
                "r/r WM",
                "r/r CLL",
                "r/r SLL",
                "Aggressive lymphoma",
                "Indolent lymphoma",
                "LCL"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "NA",
                "interventionModel": "SINGLE_GROUP",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "NONE"
                }
            },
            "enrollmentInfo": {
                "count": 150,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "NKX019 - CAR NK cell therapy",
                    "type": "EXPERIMENTAL",
                    "description": "All subjects will receive fludarabine/cyclophosphamide lymphodepletion followed by 3 weekly doses of NKX019 on Day 0, 7, and 14 of a 28-day cycle. Combination cohorts (if opened) will additionally receive rituximab with each cycle.",
                    "interventionNames": [
                        "Biological: NKX019"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "BIOLOGICAL",
                    "name": "NKX019",
                    "description": "NKX019 is an investigational allogeneic CAR NK product targeting CD19 on cells. The starting dose of NKX019 in Part 1 is 3 \u00d7 10\\^8 NK cells (6 \u00d7 10\\^6/kg for patients \\< 50 kg) administered as 3 weekly doses. Part 2 (dose expansion cohorts) will use the maximum tolerated dose (MTD) or recommended Phase 2 dose (RP2D) of NKX019 as determined in Part 1.",
                    "armGroupLabels": [
                        "NKX019 - CAR NK cell therapy"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Incidence of Treatment-Emergent Adverse Events [Safety and Tolerability]",
                    "description": "Incidence, nature, and severity of treatment related adverse events will be evaluated. An adverse event is any unfavorable and unintended sign including clinically significant abnormal laboratory findings, symptom or disease.",
                    "timeFrame": "30 days after last dose of NKX019"
                },
                {
                    "measure": "Proportion of subjects experiencing dose-limiting toxicities of NKX019",
                    "description": "DLTs are defined as adverse events attributable to NKX019 treatment that occur during Cycle 1 and meet protocol-specified criteria",
                    "timeFrame": "28 days from first dose of NKX019"
                },
                {
                    "measure": "Objective response rate to NKX019 in Part 2",
                    "description": "Percentage of subjects with complete and partial response. Response to treatment will be assessed based on: Lugano classification with LYRIC refinement for subjects with NHL (except CLL/SLL and WM); 2018 iwCLL guidelines for subjects with CLL/SLL; Version 1.2020 NCCN for subjects with B-ALL; consensus criteria from the 6th International Workshop on Waldenstr\u00f6m Macroglobulinemia for subjects with WM.",
                    "timeFrame": "Primary assessment: 28 days after the first dose of NKX019 followed up to 2 years after the last dose of NKX019]"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Assessment of NKX019 half-life",
                    "description": "Time required for 50% reduction from maximum amount of circulating NKX019",
                    "timeFrame": "Time Frame: 28 days from first dose of NKX019"
                },
                {
                    "measure": "NKX019 duration of persistence",
                    "description": "Testing NKX019 in peripheral blood every 3 months after dosing to determine persistence",
                    "timeFrame": "Followed up to 2 years after last dose of NKX019"
                },
                {
                    "measure": "Evaluation of host immune response against NKX019",
                    "description": "Serum samples will be measured for antibodies against NKX019",
                    "timeFrame": "Followed up to 2 years after last dose of NKX019"
                },
                {
                    "measure": "Objective response rate to NKX019 in Part 1",
                    "description": "Percentage of subjects with complete and partial response. Response to treatment will be assessed based on: Lugano classification with LYRIC refinement for subjects with NHL (except CLL/SLL and WM); 2018 iwCLL guidelines for subjects with CLL/SLL; Version 1.2020 NCCN for subjects with B-ALL; consensus criteria from the 6th International Workshop on Waldenstr\u00f6m Macroglobulinemia for subjects with WM.",
                    "timeFrame": "Primary assessment: 28 days after first dose of NKX019 followed up to 2 years after last dose of NKX019"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\nGeneral:\n\nEastern Cooperative Oncology Group (ECOG) performance status \u22641\n\n\u2022 Disease Related:\n\n* Have a histologically or cytologically confirmed diagnosis of r/r B cell NHL or CLL or B-ALL as defined by WHO 2016 classification\n* Subjects who received prior CD19/CD20-directed therapy must have disease that remains CD19+ and/or CD20+ respectively\n* Have measurable disease\n* Have received \u22652 lines of therapy except subjects with MCL, CAR T Na\u00efve cohorts and WM, who must have received at least 1 prior line of therapy\n* Have received a combination of an anti CD20 monoclonal antibody and cytotoxic chemotherapy for subjects with NHL\n* Received:\n\n  * BTKi for subjects with MCL, CLL/SLL, WM, and other indications where a BTKi is approved\n  * Venetoclax for subjects with CLL/SLL\n  * Tyrosine kinase inhibitor for subjects with Philadelphia chromosome (Ph+) B-ALL\n* Not responded or relapsed within 12 months of completion of their prior line of therapy, with the exception of a newly diagnosed Richter's transformation of CLL/SLL or other transformation of an indolent lymphoma, including from WM\n* Subjects must not have evidence of rapidly progressive disease that would preclude subject from completing at least 1 cycle of treatment.\n* Adequate organ function\n* White blood cell count of \u226420 \u00d7 109/L\n* Platelet count \u226530,000/uL\n\nExclusion Criteria:\n\n\u2022 Disease related:\n\n* Burkitt Lymphoma, primary central nervous system (CNS) lymphoma, Richter's transformation to Hodgkin lymphoma\n* Subjects with WM who underwent plasmapheresis \\<35 days prior to the first dose of NKX019\n* Subjects with NHL with any evidence of active CNS malignancy\n* Subjects with B-ALL who have extramedullary disease (EMD)\n* Subjects with any prior cellular therapy except subjects enrolling in selected cohorts who must have received prior CAR T therapy, recent HCT, or complications from HCT\n* Recent use of any cancer-directed therapy within protocol specified window prior to the first dose of NKX019\n* Residual toxicities \u2265Grade 2 due to prior therapy\n* Other comorbid conditions and concomitant medications prohibited as per study protocol\n* Pregnant or lactating female",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Nishi Kothari, MD",
                    "role": "CONTACT",
                    "phone": "+1 415-651-5080",
                    "email": "medmonitor@nkartatx.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "David Shook, MD",
                    "affiliation": "Nkarta, Inc.",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Colorado Blood Cancer Institute",
                    "status": "RECRUITING",
                    "city": "Denver",
                    "state": "Colorado",
                    "zip": "80218",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Michael Tees, MD",
                            "role": "CONTACT",
                            "phone": "720-754-4800"
                        },
                        {
                            "name": "Savannah Harris",
                            "role": "CONTACT",
                            "phone": "+1-720-754-8063",
                            "email": "Savannah.Harris@SarahCannon.com"
                        },
                        {
                            "name": "Michael Tees, MD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 39.73915,
                        "lon": -104.9847
                    }
                },
                {
                    "facility": "University of Chicago",
                    "status": "WITHDRAWN",
                    "city": "Chicago",
                    "state": "Illinois",
                    "zip": "60637",
                    "country": "United States",
                    "geoPoint": {
                        "lat": 41.85003,
                        "lon": -87.65005
                    }
                },
                {
                    "facility": "The Cleveland Clinic Foundation",
                    "status": "RECRUITING",
                    "city": "Cleveland",
                    "state": "Ohio",
                    "zip": "44195",
                    "country": "United States",
                    "contacts": [
                        {
                            "name": "Brian Hill, MD PhD",
                            "role": "CONTACT",
                            "phone": "216-445-9451",
                            "email": "hillb2@ccf.org"
                        },
                        {
                            "name": "Brian Hill, MD PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 41.4995,
                        "lon": -81.69541
                    }
                },
                {
                    "facility": "Institute of Haematology, Royal Prince Alfred Hospital",
                    "status": "RECRUITING",
                    "city": "Camperdown",
                    "state": "New South Wales",
                    "zip": "2050",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Christian Bryant, MBSS PhD",
                            "role": "CONTACT",
                            "phone": "+61 2 9515 8031",
                            "email": "Christian.Bryant@health.nsw.gov.au"
                        },
                        {
                            "name": "Christain Bryant, MBSS PhD",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.88965,
                        "lon": 151.17642
                    }
                },
                {
                    "facility": "St. Vincent's Hospital",
                    "status": "RECRUITING",
                    "city": "Sydney",
                    "state": "New South Wales",
                    "zip": "2010",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Louise Christophersen",
                            "role": "CONTACT",
                            "phone": "+61 2 9355 5702",
                            "email": "louise.christophersen@svha.org.au"
                        },
                        {
                            "name": "Nada Hamad, MBSS BSc",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -33.86785,
                        "lon": 151.20732
                    }
                },
                {
                    "facility": "Royal Brisbane and Woman's Hospital",
                    "status": "RECRUITING",
                    "city": "Brisbane",
                    "state": "Queensland",
                    "zip": "4029",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Glen W Kennedy, MBBS FRACP",
                            "role": "CONTACT",
                            "phone": "+61 07 3646 7962",
                            "email": "glen.kennedy@health.qld.gov.au"
                        },
                        {
                            "name": "Glen Kennedy, MBSS FRACP",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -27.46794,
                        "lon": 153.02809
                    }
                },
                {
                    "facility": "Peter MacCallum Cancer Center",
                    "status": "RECRUITING",
                    "city": "Melbourne",
                    "state": "Victoria",
                    "zip": "3000",
                    "country": "Australia",
                    "contacts": [
                        {
                            "name": "Parkville Cancer Clinical Trials Unit",
                            "role": "CONTACT",
                            "phone": "+61 3 8559 7456",
                            "email": "clinicaltrials.enquiries@petermac.org"
                        },
                        {
                            "name": "Michael Dickinson, MBSS DMedSci",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": -37.814,
                        "lon": 144.96332
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D000008223",
                    "term": "Lymphoma"
                },
                {
                    "id": "D000007938",
                    "term": "Leukemia"
                },
                {
                    "id": "D000054198",
                    "term": "Precursor Cell Lymphoblastic Leukemia-Lymphoma"
                },
                {
                    "id": "D000015451",
                    "term": "Leukemia, Lymphocytic, Chronic, B-Cell"
                },
                {
                    "id": "D000020522",
                    "term": "Lymphoma, Mantle-Cell"
                },
                {
                    "id": "D000008258",
                    "term": "Waldenstrom Macroglobulinemia"
                },
                {
                    "id": "D000008228",
                    "term": "Lymphoma, Non-Hodgkin"
                },
                {
                    "id": "D000000374",
                    "term": "Aggression"
                }
            ],
            "ancestors": [
                {
                    "id": "D000009370",
                    "term": "Neoplasms by Histologic Type"
                },
                {
                    "id": "D000009369",
                    "term": "Neoplasms"
                },
                {
                    "id": "D000008232",
                    "term": "Lymphoproliferative Disorders"
                },
                {
                    "id": "D000008206",
                    "term": "Lymphatic Diseases"
                },
                {
                    "id": "D000007160",
                    "term": "Immunoproliferative Disorders"
                },
                {
                    "id": "D000007154",
                    "term": "Immune System Diseases"
                },
                {
                    "id": "D000006402",
                    "term": "Hematologic Diseases"
                },
                {
                    "id": "D000007945",
                    "term": "Leukemia, Lymphoid"
                },
                {
                    "id": "D000015448",
                    "term": "Leukemia, B-Cell"
                },
                {
                    "id": "D000002908",
                    "term": "Chronic Disease"
                },
                {
                    "id": "D000020969",
                    "term": "Disease Attributes"
                },
                {
                    "id": "D000010335",
                    "term": "Pathologic Processes"
                },
                {
                    "id": "D000096762",
                    "term": "Aberrant Motor Behavior in Dementia"
                },
                {
                    "id": "D000001526",
                    "term": "Behavioral Symptoms"
                },
                {
                    "id": "D000054219",
                    "term": "Neoplasms, Plasma Cell"
                },
                {
                    "id": "D000020141",
                    "term": "Hemostatic Disorders"
                },
                {
                    "id": "D000014652",
                    "term": "Vascular Diseases"
                },
                {
                    "id": "D000002318",
                    "term": "Cardiovascular Diseases"
                },
                {
                    "id": "D000010265",
                    "term": "Paraproteinemias"
                },
                {
                    "id": "D000001796",
                    "term": "Blood Protein Disorders"
                },
                {
                    "id": "D000006474",
                    "term": "Hemorrhagic Disorders"
                }
            ],
            "browseLeaves": [
                {
                    "id": "M11220",
                    "name": "Lymphoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18116",
                    "name": "Leukemia, Lymphocytic, Chronic, B-Cell",
                    "asFound": "Small lymphocytic lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11222",
                    "name": "Lymphoma, Non-Hodgkin",
                    "asFound": "Lymphoma, Non-Hodgkin",
                    "relevance": "HIGH"
                },
                {
                    "id": "M18828",
                    "name": "Lymphoma, B-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M27585",
                    "name": "Precursor Cell Lymphoblastic Leukemia-Lymphoma",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10945",
                    "name": "Leukemia",
                    "asFound": "Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M10951",
                    "name": "Leukemia, Lymphoid",
                    "relevance": "LOW"
                },
                {
                    "id": "M22307",
                    "name": "Lymphoma, Mantle-Cell",
                    "asFound": "Mantle Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "M11251",
                    "name": "Waldenstrom Macroglobulinemia",
                    "asFound": "Waldenstrom Macroglobulinemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "M3724",
                    "name": "Aggression",
                    "asFound": "Aggressive",
                    "relevance": "HIGH"
                },
                {
                    "id": "M12315",
                    "name": "Neoplasms by Histologic Type",
                    "relevance": "LOW"
                },
                {
                    "id": "M11225",
                    "name": "Lymphoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M11203",
                    "name": "Lymphatic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M10206",
                    "name": "Immunoproliferative Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M10200",
                    "name": "Immune System Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M9490",
                    "name": "Hematologic Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M18115",
                    "name": "Leukemia, B-Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M6147",
                    "name": "Chronic Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "M22700",
                    "name": "Disease Attributes",
                    "relevance": "LOW"
                },
                {
                    "id": "M6904",
                    "name": "Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M3259",
                    "name": "Aberrant Motor Behavior in Dementia",
                    "relevance": "LOW"
                },
                {
                    "id": "M4818",
                    "name": "Behavioral Symptoms",
                    "relevance": "LOW"
                },
                {
                    "id": "M27588",
                    "name": "Neoplasms, Plasma Cell",
                    "relevance": "LOW"
                },
                {
                    "id": "M21977",
                    "name": "Hemostatic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M5059",
                    "name": "Blood Coagulation Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M17400",
                    "name": "Vascular Diseases",
                    "relevance": "LOW"
                },
                {
                    "id": "M13178",
                    "name": "Paraproteinemias",
                    "relevance": "LOW"
                },
                {
                    "id": "M5077",
                    "name": "Blood Protein Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "M9560",
                    "name": "Hemorrhagic Disorders",
                    "relevance": "LOW"
                },
                {
                    "id": "T3543",
                    "name": "Lymphosarcoma",
                    "asFound": "Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T1308",
                    "name": "Chronic Lymphocytic Leukemia",
                    "asFound": "Chronic Lymphocytic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T640",
                    "name": "B-cell Lymphoma",
                    "asFound": "B-cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T175",
                    "name": "Acute Lymphoblastic Leukemia",
                    "asFound": "Acute Lymphoblastic Leukemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T3533",
                    "name": "Lymphoblastic Lymphoma",
                    "relevance": "LOW"
                },
                {
                    "id": "T1303",
                    "name": "Chronic Graft Versus Host Disease",
                    "relevance": "LOW"
                },
                {
                    "id": "T3601",
                    "name": "Mantle Cell Lymphoma",
                    "asFound": "Mantle Cell Lymphoma",
                    "relevance": "HIGH"
                },
                {
                    "id": "T5887",
                    "name": "Waldenstrom Macroglobulinemia",
                    "asFound": "Waldenstrom Macroglobulinemia",
                    "relevance": "HIGH"
                },
                {
                    "id": "T170",
                    "name": "Acute Graft Versus Host Disease",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "BC04",
                    "name": "Neoplasms"
                },
                {
                    "abbrev": "BC15",
                    "name": "Blood and Lymph Conditions"
                },
                {
                    "abbrev": "BC20",
                    "name": "Immune System Diseases"
                },
                {
                    "abbrev": "All",
                    "name": "All Conditions"
                },
                {
                    "abbrev": "BC23",
                    "name": "Symptoms and General Pathology"
                },
                {
                    "abbrev": "BC14",
                    "name": "Heart and Blood Diseases"
                },
                {
                    "abbrev": "BXM",
                    "name": "Behaviors and Mental Disorders"
                },
                {
                    "abbrev": "BC10",
                    "name": "Nervous System Diseases"
                },
                {
                    "abbrev": "Rare",
                    "name": "Rare Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "browseLeaves": [
                {
                    "id": "M6727",
                    "name": "Cyclophosphamide",
                    "relevance": "LOW"
                },
                {
                    "id": "M2853",
                    "name": "Immunomodulating Agents",
                    "relevance": "LOW"
                },
                {
                    "id": "M373",
                    "name": "Rituximab",
                    "relevance": "LOW"
                },
                {
                    "id": "M283230",
                    "name": "Fludarabine",
                    "relevance": "LOW"
                },
                {
                    "id": "M225513",
                    "name": "Fludarabine phosphate",
                    "relevance": "LOW"
                }
            ],
            "browseBranches": [
                {
                    "abbrev": "ANeo",
                    "name": "Antineoplastic Agents"
                },
                {
                    "abbrev": "ARhu",
                    "name": "Antirheumatic Agents"
                },
                {
                    "abbrev": "All",
                    "name": "All Drugs and Chemicals"
                }
            ]
        }
    },
    "hasResults": false
}